HIV-1 integrase binding to its cellular partners: A perspective from computational biology

Vo Cam Quy, Vincenzo Carnevale, Lara Manganaro, Marina Lusic, Giulia Rossetti, Vanessa Leone, Cristina Fenollar-Ferrer, Simone Raugei, Giannino Del Sal, Mauro Giacca, Paolo Carloni

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Viral DNA integration into the infected cell genome is an essential step in the HIV-1 life cycle. Hence, the viral integrase enzyme has become an important target for antiviral therapy. The integrase's activity action relies on the binding to its cellular partners, therefore the knowledge of the structural determinants is very important from a therapeutic perspective. Here we first review published computer-aided structural predictions of HIV-1 integrase in complex with its interactors. These include DNA and the human HAT protein. Next, we present a prediction of the complex between HIV-1 integrase with the human prolyl-isomerase-1 (hPin1) enzyme. Interaction with hPin1 is crucial for efficient HIV-1 infection and it increases integrase stability (Manganaro et. al 2010, Nat. Med. 16, 329). The modeling presented here, which is validated against experimental data, provides a rationale for a variety of viral protein's mutations which impair protein function and HIV-1 virus replication in vivo without significantly affecting enzymatic activity.

Original languageEnglish
Pages (from-to)3412-3421
Number of pages10
JournalCurrent Pharmaceutical Design
Volume20
Issue number21
DOIs
Publication statusPublished - 2014

Fingerprint

Integrases
Computational Biology
HIV-1
Peptidylprolyl Isomerase
Virus Integration
Viral DNA
Viral Proteins
Enzymes
Virus Replication
Life Cycle Stages
HIV Infections
Antiviral Agents
Proteins
Genome
Mutation
DNA
Therapeutics
p31 integrase protein, Human immunodeficiency virus 1

Keywords

  • Class II mutant
  • HIV-1 integrase
  • Human Pin1
  • Protein-protein interaction

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Medicine(all)

Cite this

Quy, V. C., Carnevale, V., Manganaro, L., Lusic, M., Rossetti, G., Leone, V., ... Carloni, P. (2014). HIV-1 integrase binding to its cellular partners: A perspective from computational biology. Current Pharmaceutical Design, 20(21), 3412-3421. https://doi.org/10.2174/13816128113199990631

HIV-1 integrase binding to its cellular partners : A perspective from computational biology. / Quy, Vo Cam; Carnevale, Vincenzo; Manganaro, Lara; Lusic, Marina; Rossetti, Giulia; Leone, Vanessa; Fenollar-Ferrer, Cristina; Raugei, Simone; Del Sal, Giannino; Giacca, Mauro; Carloni, Paolo.

In: Current Pharmaceutical Design, Vol. 20, No. 21, 2014, p. 3412-3421.

Research output: Contribution to journalArticle

Quy, VC, Carnevale, V, Manganaro, L, Lusic, M, Rossetti, G, Leone, V, Fenollar-Ferrer, C, Raugei, S, Del Sal, G, Giacca, M & Carloni, P 2014, 'HIV-1 integrase binding to its cellular partners: A perspective from computational biology', Current Pharmaceutical Design, vol. 20, no. 21, pp. 3412-3421. https://doi.org/10.2174/13816128113199990631
Quy, Vo Cam ; Carnevale, Vincenzo ; Manganaro, Lara ; Lusic, Marina ; Rossetti, Giulia ; Leone, Vanessa ; Fenollar-Ferrer, Cristina ; Raugei, Simone ; Del Sal, Giannino ; Giacca, Mauro ; Carloni, Paolo. / HIV-1 integrase binding to its cellular partners : A perspective from computational biology. In: Current Pharmaceutical Design. 2014 ; Vol. 20, No. 21. pp. 3412-3421.
@article{c41a79cbc422432f8849a4abaac75af8,
title = "HIV-1 integrase binding to its cellular partners: A perspective from computational biology",
abstract = "Viral DNA integration into the infected cell genome is an essential step in the HIV-1 life cycle. Hence, the viral integrase enzyme has become an important target for antiviral therapy. The integrase's activity action relies on the binding to its cellular partners, therefore the knowledge of the structural determinants is very important from a therapeutic perspective. Here we first review published computer-aided structural predictions of HIV-1 integrase in complex with its interactors. These include DNA and the human HAT protein. Next, we present a prediction of the complex between HIV-1 integrase with the human prolyl-isomerase-1 (hPin1) enzyme. Interaction with hPin1 is crucial for efficient HIV-1 infection and it increases integrase stability (Manganaro et. al 2010, Nat. Med. 16, 329). The modeling presented here, which is validated against experimental data, provides a rationale for a variety of viral protein's mutations which impair protein function and HIV-1 virus replication in vivo without significantly affecting enzymatic activity.",
keywords = "Class II mutant, HIV-1 integrase, Human Pin1, Protein-protein interaction",
author = "Quy, {Vo Cam} and Vincenzo Carnevale and Lara Manganaro and Marina Lusic and Giulia Rossetti and Vanessa Leone and Cristina Fenollar-Ferrer and Simone Raugei and {Del Sal}, Giannino and Mauro Giacca and Paolo Carloni",
year = "2014",
doi = "10.2174/13816128113199990631",
language = "English",
volume = "20",
pages = "3412--3421",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "21",

}

TY - JOUR

T1 - HIV-1 integrase binding to its cellular partners

T2 - A perspective from computational biology

AU - Quy, Vo Cam

AU - Carnevale, Vincenzo

AU - Manganaro, Lara

AU - Lusic, Marina

AU - Rossetti, Giulia

AU - Leone, Vanessa

AU - Fenollar-Ferrer, Cristina

AU - Raugei, Simone

AU - Del Sal, Giannino

AU - Giacca, Mauro

AU - Carloni, Paolo

PY - 2014

Y1 - 2014

N2 - Viral DNA integration into the infected cell genome is an essential step in the HIV-1 life cycle. Hence, the viral integrase enzyme has become an important target for antiviral therapy. The integrase's activity action relies on the binding to its cellular partners, therefore the knowledge of the structural determinants is very important from a therapeutic perspective. Here we first review published computer-aided structural predictions of HIV-1 integrase in complex with its interactors. These include DNA and the human HAT protein. Next, we present a prediction of the complex between HIV-1 integrase with the human prolyl-isomerase-1 (hPin1) enzyme. Interaction with hPin1 is crucial for efficient HIV-1 infection and it increases integrase stability (Manganaro et. al 2010, Nat. Med. 16, 329). The modeling presented here, which is validated against experimental data, provides a rationale for a variety of viral protein's mutations which impair protein function and HIV-1 virus replication in vivo without significantly affecting enzymatic activity.

AB - Viral DNA integration into the infected cell genome is an essential step in the HIV-1 life cycle. Hence, the viral integrase enzyme has become an important target for antiviral therapy. The integrase's activity action relies on the binding to its cellular partners, therefore the knowledge of the structural determinants is very important from a therapeutic perspective. Here we first review published computer-aided structural predictions of HIV-1 integrase in complex with its interactors. These include DNA and the human HAT protein. Next, we present a prediction of the complex between HIV-1 integrase with the human prolyl-isomerase-1 (hPin1) enzyme. Interaction with hPin1 is crucial for efficient HIV-1 infection and it increases integrase stability (Manganaro et. al 2010, Nat. Med. 16, 329). The modeling presented here, which is validated against experimental data, provides a rationale for a variety of viral protein's mutations which impair protein function and HIV-1 virus replication in vivo without significantly affecting enzymatic activity.

KW - Class II mutant

KW - HIV-1 integrase

KW - Human Pin1

KW - Protein-protein interaction

UR - http://www.scopus.com/inward/record.url?scp=84903727821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903727821&partnerID=8YFLogxK

U2 - 10.2174/13816128113199990631

DO - 10.2174/13816128113199990631

M3 - Article

C2 - 24001231

AN - SCOPUS:84903727821

VL - 20

SP - 3412

EP - 3421

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 21

ER -